Frost & Sullivan Commends Nycomed for Excellence in Product Differentiation Innovation

LONDON - The “2008 European Tissue Sealants & Topical Hemostats Product
Differentiation Innovation Award” is conferred on Nycomed in recognition of
its revolutionary product - TachoSil. The innovative surgical patch, TachoSil
is poised to be the future of the European tissue sealants and topical
hemostats markets.

(Logo: www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

At present, Nycomed, with TachoSil, is the sole company in the market
with a ready-to-use dual action patch. TachoSil is unique: it does not fit
into any of the standard market segments and constitutes a separate category
on its own.

“This pioneering product has both haemostatic and sealing properties and
can be used to stop bleeding as well seal tissue,” explains Frost & Sullivan
Research Analyst Divya Belle. “TachoSil combines the bioactive mechanism of
action of human coagulation factors fibrinogen and thrombin with a collagen
patch for mechanical support.”

TachoSil effectively fulfills the market need for an easy-to-use product
with ready-to-use features. TachoSil is safely absorbed by the body within
weeks after application. It can be stored at room temperature and is
available in three different sized patches which require no preparation
before surgical use. Additionally, it minimizes the risk of post-operative
re-bleedings, reducing hospital stays and the need for re-operations.

Moreover, due to its strong hemostatic and sealing properties, TachoSil
meets the need for products that are able to control bleeding and seal tissue
during surgeries. Such multiple attributes have underlined the competitive
edge enjoyed by TachoSil.

Most fibrin sealants or hemostats available in the market today are
bovine-based. These products have attendant safety concerns related to the
bovine protein Aprotinin or bovine thrombin which carries the risk of
allergic reactions, autoimmune syndromes and transfer of diseases.

“With TachoSil, Nycomed has eliminated Aprotinin, offering a product that
is free of bovine components,” states Belle. “Accordingly, there is no risk
of transmittance of bovine diseases since it contains only the coagulation
factors - human fibrinogen and human thrombin.”

TachoSil has been registering high growth rates of over 20 per cent.
Testifying to its efficacy and potential for continued success is the recent
agreement entered into by Nycomed with Baxter International, with the latter
set to market and distribute the TachoSil patch in the United States, after
approval.

The Frost & Sullivan Award for Product Differentiation Innovation is
presented to the company that has best demonstrated the ability to develop
and/or advance products with more innovative capabilities than competing
vendors and products. This Award recognises the company’s successful adoption
of new or existing technology that has become a part of its well-designed
product family. Such innovation is expected to significantly contribute to
the industry in terms of product performance and degree/rate of technical
change.

Frost & Sullivan Best Practices Awards recognise companies in a variety
of regional and global markets for demonstrating outstanding achievement and
superior performance in areas such as leadership, technological innovation,
customer service, and strategic product development. Industry analysts
compare market participants and measure performance through in-depth
interviews, analysis, and extensive secondary research in order to identify
best practices in the industry.

About Nycomed

Nycomed is a privately owned global pharmaceutical company with a
differentiated portfolio focused on branded medicines in gastroenterology,
respiratory and inflammatory diseases, pain, osteoporosis and tissue
management.

Its R&D is built to be open for partnerships as in-licensing is a
cornerstone in the company’s growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are
available in more than 100 countries. It has strong platforms in Europe and
in fast-growing markets such as Russia/CIS, and Latin America. While the US
and Japan are commercialised through best-in-class partners, Nycomed will
further strengthen its position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated in 2008 total
sales of euro 3,4 billion and an adjusted EBITDA of euro 1,2 billion.

For more information visit www.nycomed.com

Nycomed Contact Information

Jorgen Persson
International Marketing Unit Director
Nycomed Group
P.O. Box 88
Langebjerg 1
DK-4000 Roskilde, Denmark
Direct Line: +45-46-77-10-57
Mobile: +45-40-95-51-57
Fax: +45-46-75-79-34
E-mail: Joergen.Persson@nycomed.com
www.nycomed.com

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients
to accelerate their growth. The company’s TEAM Research, Growth Consulting
and Growth Team Membership(TM) empower clients to create a growth-focused
culture that generates, evaluates and implements effective growth strategies.
Frost & Sullivan employs over 45 years of experience in partnering with
Global 1000 companies, emerging businesses and the investment community from
more than 30 offices on six continents. For more information about Frost &
Sullivan’s Growth Partnership Services, visit www.frost.com.

Frost & Sullivan Contact Information
Jasmine Malone - Promotions Coordinator
Phone: +44-207-915-7869
E-Mail: jasmine.malone@frost.com

Source: Frost & Sullivan

Jorgen Persson, International Marketing Unit Director of Nycomed Group, +45-46-77-10-57, mobile, +45-40-95-51-57, fax, +45-46-75-79-34, Joergen.Persson at nycomed.com; or Jasmine Malone, Promotions Coordinator of Frost & Sullivan, 0044 207 915 7869, jasmine.malone at frost.com